Clinical characteristics of patients with Vα2.3+ T-cells >10.5% in bronchoalveolar lavage fluid (BALF)
| LS | Non-LS | |
| Subjects | 180 | 68 |
| Male/female | 111/69 | 41/27 |
| Age years# | 37 (21–62) | 45 (26–72) |
| Radiographic stage 0/I/II/III/IV# | 0/123/57/0/0 | 4/16/36/8/4 |
| Resolving/non-resolving# | 166/14 | 25/43 |
| CD4/CD8 ratio* | 9.8 (0.9–56.8) | 7.1 (1.2–24.0) |
| % Vα2.3 BALF cells# | 28.4 (11.0–50.0) | 17.8 (11.4–44.3) |
| HLA-DRB1*03+/− | 155/25 | 36/32 |
| Vα2.3 BALF cells % | ||
| HLA-DRB1*03+# | 29.9 | 20.5 |
| HLA-DRB1*03−** | 19.8 | 14.8 |
| Patients recovered % | ||
| HLA-DRB1*03+# | 94 | 39 |
| HLA-DRB1*03−** | 80 | 34 |
Data are presented as n or mean (range), unless otherwise stated. LS: Löfgreńs syndrome. *: p<0.05, **: p<0.001 and #: p<0.0001, comparing differences between patients with LS and non-LS and for radiological stage differences between stage I and II.